BIOBV.HE
Biohit Oyj
Price:  
2.10 
EUR
Volume:  
12,191.00
Finland | Health Care Equipment & Supplies
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

BIOBV.HE WACC - Weighted Average Cost of Capital

The WACC of Biohit Oyj (BIOBV.HE) is 6.5%.

The Cost of Equity of Biohit Oyj (BIOBV.HE) is 6.20%.
The Cost of Debt of Biohit Oyj (BIOBV.HE) is 14.75%.

Range Selected
Cost of equity 5.30% - 7.10% 6.20%
Tax rate 13.10% - 15.20% 14.15%
Cost of debt 4.00% - 25.50% 14.75%
WACC 5.2% - 7.8% 6.5%
WACC

BIOBV.HE WACC calculation

Category Low High
Long-term bond rate 2.7% 3.2%
Equity market risk premium 5.7% 6.7%
Adjusted beta 0.36 0.43
Additional risk adjustments 0.5% 1.0%
Cost of equity 5.30% 7.10%
Tax rate 13.10% 15.20%
Debt/Equity ratio 0.05 0.05
Cost of debt 4.00% 25.50%
After-tax WACC 5.2% 7.8%
Selected WACC 6.5%

BIOBV.HE's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for BIOBV.HE:

cost_of_equity (6.20%) = risk_free_rate (2.95%) + equity_risk_premium (6.20%) * adjusted_beta (0.36) + risk_adjustments (0.75%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.